Molecular evolution of rectal cancer and prediction of response

• Research type

  Research Study

• Full title

  Molecular evolution of rectal cancer and prediction of response to neoadjuvant therapy

• IRAS ID

  246347

• Contact name

  Dale Vimalachandran

• Contact email

  dale.vimalachandran@nhs.net

• Sponsor organisation

  Countess of Chester Hospital

• Duration of Study in the UK

  4 years, 11 months, 31 days

• Research summary

  We aim to establish a mechanism and framework to recruit and screen patients with locally advanced rectal cancer in order to evaluate the specific biology of the tumour, such that we can improve response to cancer therapy. The first part of this (this study) is to establish a research infrastructure and biopsy template so that all future studies will have sufficient cancer material for downstream analysis.

• REC name

  North West - Greater Manchester West Research Ethics Committee

• REC reference

  18/NW/0543

• Date of REC Opinion

  5 Sep 2018

• REC opinion

  Further Information Favourable Opinion